pharma · Locally advanced or metastatic urothelial cancer · Nectin-4 Expressing Advanced Malignancies. · BCYC
BICYCLE THERAPEUTICS
BICYCLE THERAPEUTICS patent portfolio — 57 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, GB
- Founded
- 2009
- Employees
- 282
- Programs
- 8
- Drugs
- 15
- Patents
- 57
BICYCLE THERAPEUTICS patents
57 pharmaceutical patents indexed for BICYCLE THERAPEUTICS. 0 expire within 24 months.
BICYCLE THERAPEUTICS has 57 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 10118947
Modulation of structured polypeptide specificity
granted -
US 9994617
Modulation of structured polypeptide specificity
granted -
US 9670484
Methods and compositions
granted -
US 9670482
Multispecific peptides
granted -
US 9657288
Connector compound peptide phage display
granted -
US 9644201
Structured peptide processing
granted -
US 8778844
Structured peptide processing
granted -
US 8685890
Multispecific peptides
granted -
US 8680022
Methods and compositions
granted
Frequently asked questions
How many patents does BICYCLE THERAPEUTICS have?
57 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do BICYCLE THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.